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Introduction
Severe sepsis and septic shock are serious conditions
associated with high mortality, especially in the patients
complicated with acute respiratory distress syndrome
(ARDS). Corticosteroids are recommended in patients
who do not respond to fluid resuscitation and vasopres-
sors. However, efficacy of this treatment in severe sepsis
patients with ARDS has not been investigated.
Objectives
To examine efficacy of moderate dose of hydrocortisone
in the treatment of severe sepsis/septic shock compli-
cated with ARDS.
Methods
A single center, placebo-controlled, randomized, double
blind study which included adult patients with severe
sepsis or septic shock and ARDS, onset within 24 hours.
They were randomly assigned into two groups. The
“study group” received hydrocortisone 50 mg intravenous
every 6 hours for 7 days, while the “controlled group”
received normal saline in the comparable volume. The
primary outcome was 28 days mortality.
Results
A total of 197 patients were included. Ninety eight were in
“study group” and 99 were in the “control group”. While
baseline characteristics were similar, the study group had
longer organ support-free days in the 28 days (13.9+10.3
vs 10.8+10.1, P = 0.04), shorter vasopressor-dependent
days (3.8+3.3 vs 5.2+5.7, P = 0.04), lower lung injury score
at the 3rd day after treatment (1.5+0.8 vs 1.8+1.0, P = 0.03)
and improve PaO2/FiO2 ratio at the 3
rd day after treatment
(273.9+126.9 vs 227.6+110.3, P = 0.007). The incidence of
hyperglycemia was also higher in the study group. Mortal-
ity in the study group was lower although statistical differ-
ence was not reached (25.5% vs 31.3%, P = 0.37).
Conclusions
Hydrocortisone improved outcomes; namely organ sup-
port-free days, vasopressor-dependent days and oxygena-
tion, in severe sepsis or septic shock patients with ARDS.
There was a trend toward mortality reduction in the
study group but the statistical significant was not
reached. (ClinicalTrials.gov number, NCT01284452)
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